The company has scaled back its headcount from a peak of 115 employees to about 100 staff members, primarily on the commercial side.
The gene editing firm has sold all 5.9 million shares offered to the public as well as 885,000 shares in the fully exercised over-allotment option to the underwriters.
The Cambridge, Massachusetts-based gene editing firm will offer 5.9 million shares of common stock, for a total of $94.4 million.
The Cambridge, Massachusetts-based CRISPR therapy firm expects to price shares between $16 and $18.
The German molecular diagnostics firm plans to list on Euronext in Amsterdam and Euronext in Brussels.
Market worries earlier this week have left some in biotech shaken, FierceBiotech says.
The company filed to go public in March with plans to offer up to $60 million of its stock.
The firm will withdraw its planned IPO after being told that it would have to take a 30 to 40 percent discount to its valuation, its CEO said.
The $180 million offering is well above the firm's initial target for proceeds of $100 million.
The firm said in an SEC document that it plans to offer 6.25 million shares and expects net proceeds of up to $103.3 million.
According to Gizmodo, researchers have developed a list of a million nucleic acid-like polymers that could store genetic information.
An opinion piece in the Washington Post argues that golden rice could save the sight and lives of many children.
US National Institutes of Health has issued a new draft data-sharing policy, ScienceInsider reports.
In Cell this week: analysis of immune microenvironment in hepatocellular carcinoma, proteogenomic analysis of clear cell renal cell carcinoma, and more.